公开(公告)号：US20240316216A1

公开(公告)日：2024-09-26

申请号：US18698888

申请日：2022-10-06

Applicant: Massachusetts Institute of Technology

Inventor： Robert S. Langer ,  Li-Huei Tsai ,  Owen Shea Fenton ,  Joel Blanchard ,  Jason Andresen ,  Julia Bonner ,  William Ralvenius

IPC: A61K48/00 ,  A61K47/14 ,  A61K47/28

CPC classification number: A61K48/0033 ,  A61K47/14 ,  A61K47/28 ,  A61K48/0058

Abstract: Provided herein are methods of selectively delivering an agent to a cell, comprising contacting the cell with a composition comprising an agent and lipids selected from: (a) an ionizable amino lipid, (b) a sterol, (c) a phospholipid, and (d) a PEG-lipid. The methods are selective for delivery to microglia over other neuroglia, such as astrocytes.

公开(公告)号：US20220411751A1

公开(公告)日：2022-12-29

申请号：US17778270

申请日：2020-11-20

Applicant: Oleg BUTOVSKY ,  Vladimir LITVAK ,  William RALVENIUS ,  Li-Huei TSAI ,  The Brigham and Women's Hospital, Inc. ,  University of Massachusetts ,  Massachusetts Institute of Technology

Inventor： Oleg Butovsky ,  Vladimir Litvak ,  William Ralvenius ,  Li-Huei Tsai

IPC: C12N5/079 ,  A61K35/30

Abstract: Provided herein are methods for obtaining populations of reprogrammed MO-homeostatic tolerogenic microglial cells. The methods include providing an initial population of monocytes, e.g., peripheral blood monocytes (PBMC), from a subject, and reprogramming the cells by maintaining the PBMC in culture ex vivo in the presence of a sufficient amount of transforming growth factor-beta (TGFβ) and interferon-gamma (IFNγ) for a time and under conditions sufficient for the cells to become M0-homeostatic tolerogenic microglia. Also provided are methods of use of these cells, e.g., for the treatment of neurodegenerative diseases associated with inflammation, e.g., Alzheimer's Disease (AD); Multiple Sclerosis (MS), e.g., progressive MS; and Amyotrophic Lateral Sclerosis